Literature DB >> 22459416

Mortality in rheumatoid arthritis over the last fifty years: systematic review and meta-analysis.

Sabrina Dadoun1, Nadine Zeboulon-Ktorza, Christophe Combescure, Muriel Elhai, Sylvie Rozenberg, Laure Gossec, Bruno Fautrel.   

Abstract

OBJECTIVE: Mortality rates in patients with rheumatoid arthritis (RA) have been reported to be higher than for the general population. Fortunately, efficient therapies have reduced disease activity and may be able to diminish the excess mortality risk. This study was designed to investigate RA mortality over the last 50 years by systematic review of the literature and meta-analysis.
METHODS: Data to January 2010 in the Medline, Cochrane and Embase databases were searched with the keywords "rheumatoid arthritis", "epidemiologic methods" and "mortality". Inclusion criteria were (i) longitudinal study, (ii) early RA patients, (iii) number of deaths and mean patient follow-up. Incidence mortality rates (IMR) were calculated and standardized mortality rates (SMR) were extracted when available. A meta-analysis by periods of inclusion and a Poisson regression were used to model IMR. Available SMR were computed as a meta-analysis.
RESULTS: A total of 11 longitudinal studies starting from 1955 to 1995, representing 51,819 patients, met the inclusion criteria. Mean IMR was 2.7/100 person-years of follow-up (95% confidence interval [CI]: 2.2, 3.3) and ranged from 1.0 to 5.2/100 person-years. A decreasing IMR was found in the meta-analyses. Poisson regression analysis indicated a decrease in IMR of 2.3% per year (95%CI: 2.1; 2.6). SMR was available in 8 studies: the meta-SMR was 1.47 (95%CI: 1.19; 1.83) and no decrease was seen over time in the meta-regression.
CONCLUSION: Mortality has decreased among RA patients over the past decades but remained higher than in the general population as assessed by the IMR and the SMR over time.
Copyright © 2012 Société française de rhumatologie. Published by Elsevier SAS. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22459416     DOI: 10.1016/j.jbspin.2012.02.005

Source DB:  PubMed          Journal:  Joint Bone Spine        ISSN: 1297-319X            Impact factor:   4.929


  72 in total

1.  Rheumatoid Arthritis and Mortality Among Women During 36 Years of Prospective Follow-Up: Results From the Nurses' Health Study.

Authors:  Jeffrey A Sparks; Shun-Chiao Chang; Katherine P Liao; Bing Lu; Alexander R Fine; Daniel H Solomon; Karen H Costenbader; Elizabeth W Karlson
Journal:  Arthritis Care Res (Hoboken)       Date:  2016-06       Impact factor: 4.794

Review 2.  Cardiovascular and Metabolic Comorbidities in Rheumatoid Arthritis.

Authors:  Silvio Romano; Elisa Salustri; Piero Ruscitti; Francesco Carubbi; Maria Penco; Roberto Giacomelli
Journal:  Curr Rheumatol Rep       Date:  2018-11-05       Impact factor: 4.592

Review 3.  Sarilumab for Previously-Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Authors:  Iñigo Bermejo; Shijie Ren; Emma Simpson; Mark Clowes; David L Scott; Adam Young; Matt Stevenson
Journal:  Pharmacoeconomics       Date:  2018-12       Impact factor: 4.981

4.  Comorbid conditions are associated with healthcare utilization, medical charges and mortality of patients with rheumatoid arthritis.

Authors:  Guang-Ming Han; Xiao-Feng Han
Journal:  Clin Rheumatol       Date:  2016-04-23       Impact factor: 2.980

5.  Improvement in 5-year mortality in incident rheumatoid arthritis compared with the general population-closing the mortality gap.

Authors:  Diane Lacaille; J Antonio Avina-Zubieta; Eric C Sayre; Michal Abrahamowicz
Journal:  Ann Rheum Dis       Date:  2016-12-28       Impact factor: 19.103

6.  Tumor necrosis factor α induces sustained signaling and a prolonged and unremitting inflammatory response in rheumatoid arthritis synovial fibroblasts.

Authors:  Angela Lee; Yu Qiao; Galina Grigoriev; Janice Chen; Kyung-Hyun Park-Min; Sung Ho Park; Lionel B Ivashkiv; George D Kalliolias
Journal:  Arthritis Rheum       Date:  2013-04

Review 7.  Cardiovascular risk in rheumatoid arthritis: assessment, management and next steps.

Authors:  Thomas Zegkos; George Kitas; Theodoros Dimitroulas
Journal:  Ther Adv Musculoskelet Dis       Date:  2016-04-30       Impact factor: 5.346

8.  Inflammatory but not mitogenic contexts prime synovial fibroblasts for compensatory signaling responses to p38 inhibition.

Authors:  Douglas S Jones; Anne P Jenney; Brian A Joughin; Peter K Sorger; Douglas A Lauffenburger
Journal:  Sci Signal       Date:  2018-03-06       Impact factor: 8.192

Review 9.  Tofacitinib for Treating Rheumatoid Arthritis After the Failure of Disease-Modifying Anti-rheumatic Drugs: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Authors:  Lesley Uttley; Iñigo Bermejo; Shijie Ren; Marrissa Martyn-St James; Ruth Wong; David L Scott; Adam Young; Matt Stevenson
Journal:  Pharmacoeconomics       Date:  2018-09       Impact factor: 4.981

Review 10.  The Roles of Cigarette Smoking and the Lung in the Transitions Between Phases of Preclinical Rheumatoid Arthritis.

Authors:  Jeffrey A Sparks; Elizabeth W Karlson
Journal:  Curr Rheumatol Rep       Date:  2016-03       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.